Pursuant to section 10 of the German Securities Prospectus Act (WpPG), which entered into force on July 1, 2005, listed companies are obliged to make annually available to the public a document containing information published or made available to the public within the preceding twelve months in order to comply with certain regulations under German corporate and capital market law. This annual document refers to the period of January 1 to December 31, 2005.
Ad hoc Releases (§ 15 WpHG)
 |
|
|
|
|
|
December 19, 2005 |
Ad hoc: Epigenomics DNA methylation test successfully detects colorectal cancer in blood |
|
|
PDF-file 89kb |
|
|
|
|
|
|
|
December 13, 2005 |
Ad hoc: Milestone and licensing decision on tamoxifen response test postponed to end of January 2006 |
|
|
PDF-file 45kb |
|
|
|
|
|
|
|
November 15, 2005 |
Ad hoc: Epigenomics AG announces end of VC pooling |
|
|
PDF-file 72kb |
|
|
|
|
|
|
|
October 31, 2005 |
Ad hoc: Epigenomics reports Tamoxifen treatment response test study results inconclusive |
|
|
PDF-file 28kb |
|
|
|
|
|
|
|
September 30, 2005 |
Ad hoc: Epigenomics and Roche Diagnostics extend R&D collaboration agreement |
|
|
PDF-file 44kb |
|
|
|
|
|
|
|
September 12, 2005 |
Ad hoc: Epigenomics AG announces resignation of Aron Braun |
|
|
PDF-file 44kb |
|
|
|
|
|
|
|
August 15, 2005 |
Ad hoc: Retiring Epigenomics executive Gary Schweikhardt released from lock-up at year-end |
|
|
PDF-file 44kb |
|
|
|
|
|
|
|
August 2, 2005 |
Ad hoc: Epigenomics AG announces Gary Schweikhardt to retire |
|
|
PDF-file 29kb |
|
|
|
|
|
|
|
May 2, 2005 |
Ad hoc: Epigenomics and QIAGEN Enter into Strategic Collaboration in DNA Methylation |
|
|
PDF-file 24kb |
|
|
|
|
|
|
|
January 20, 2005 |
Ad hoc: Epigenomics AG Announces End of Lock-Up Period |
|
|
PDF-file 19,2kb |
Directors' Dealings (§ 15a WpHG)
Releases about Directors’ Dealings in 2005
Releases about the changes in the proportion of voting rights (§ 25 Abs. 1 WpHG)
|
